NASDAQ:PCSA Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis $1.67 +0.01 (+0.60%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.67▼$1.7450-Day Range$1.48▼$2.2452-Week Range$1.40▼$18.00Volume9,482 shsAverage Volume1.33 million shsMarket Capitalization$4.78 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Processa Pharmaceuticals alerts: Email Address Processa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside379.0% Upside$8.00 Price TargetShort InterestHealthy1.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.90) to ($2.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.87 out of 5 stars 3.3 Analyst's Opinion Consensus RatingProcessa Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageProcessa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Processa Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.94% of the float of Processa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverProcessa Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Processa Pharmaceuticals has recently decreased by 28.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProcessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthProcessa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCSA. Previous Next 3.2 News and Social Media Coverage News SentimentProcessa Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Processa Pharmaceuticals this week, compared to 1 article on an average week.Search Interest4 people have searched for PCSA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Processa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Processa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders22.20% of the stock of Processa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.93% of the stock of Processa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Processa Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Processa Pharmaceuticals are expected to grow in the coming year, from ($3.90) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Processa Pharmaceuticals is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Processa Pharmaceuticals is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProcessa Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Processa Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Processa Pharmaceuticals Stock (NASDAQ:PCSA)Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.Read More PCSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCSA Stock News HeadlinesJuly 19, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Names Russell Skibsted CFO - Quick FactsJuly 19, 2024 | msn.comProcessa Pharmaceuticals appoints CFOJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…June 11, 2024 | globenewswire.comProcessa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal CancerMay 6, 2024 | globenewswire.comProcessa Pharmaceuticals to Participate in the EF Hutton Annual Global ConferenceApril 30, 2024 | globenewswire.comProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical ResearchApril 26, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Processa Pharmaceuticals (PCSA) with Buy RecommendationApril 11, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 1.09%July 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…April 11, 2024 | finance.yahoo.comProcessa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b TrialApril 7, 2024 | finance.yahoo.comInsider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40kMarch 28, 2024 | nz.finance.yahoo.comEva Mendes says she had 'non-verbal agreement' with Ryan Gosling to be a stay-at-home momMarch 28, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comProcessa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingFebruary 24, 2024 | msn.comProcessa Pharmaceuticals (PCSA) Price Target Increased by 1900.00% to 81.60February 21, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 14, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceSee More Headlines Receive PCSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PCSA CUSIPN/A CIK1533743 Webwww.processapharmaceuticals.com Phone(443) 776-3133Fax443-288-4420Employees13Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+373.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-130.15% Return on Assets-115.92% Debt Debt-to-Equity RatioN/A Current Ratio9.69 Quick Ratio9.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.05 per share Price / Book0.42Miscellaneous Outstanding Shares2,860,000Free Float2,224,000Market Cap$4.83 million OptionableNot Optionable Beta0.60 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. George K. Ng Esq. (Age 50)J.D., CEO & Director Comp: $402.03kDr. David Young Ph.D. (Age 71)Pharm.D., Co-Founder, President of Research and Development & Director Comp: $160.2kDr. Sian E. Bigora Ph.D. (Age 64)Pharm.D., Co-Founder and Chief Development & Regulatory Officer Comp: $184.87kMr. James H. Stanker (Age 66)Chief Financial Officer Comp: $160.2kMr. Patrick Lin (Age 59)Co-Founder, Chief Business & Strategy Officer Comp: $117.15kMs. Wendy J. Guy (Age 60)Co-Founder, Chief Administrative Officer & Corporate Secretary Comp: $94.19kDr. Steven Cha M.D.Senior Vice President of Clinical ResearchMore ExecutivesKey CompetitorsViracta TherapeuticsNASDAQ:VIRXVincerx PharmaNASDAQ:VINCSynlogicNASDAQ:SYBXConduit PharmaceuticalsNASDAQ:CDTLongeveronNASDAQ:LGVNView All CompetitorsInsidersDavid YoungBought 21,000 shares on 2/7/2024Total: $51,450.00 ($2.45/share)Patrick LinBought 2,500 shares on 1/31/2024Total: $5,925.00 ($2.37/share)Justin W YorkeBought 8,000 shares on 1/30/2024Total: $21,520.00 ($2.69/share)George K NgBought 10,000 shares on 1/30/2024Total: $27,000.00 ($2.70/share)View All Insider Transactions PCSA Stock Analysis - Frequently Asked Questions How have PCSA shares performed this year? Processa Pharmaceuticals' stock was trading at $6.6920 at the beginning of the year. Since then, PCSA stock has decreased by 75.0% and is now trading at $1.67. View the best growth stocks for 2024 here. How were Processa Pharmaceuticals' earnings last quarter? Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) posted its quarterly earnings results on Friday, May, 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.18) by $0.07. When did Processa Pharmaceuticals' stock split? Processa Pharmaceuticals's stock reverse split on the morning of Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Processa Pharmaceuticals? Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCSA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Processa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
